Oncolytic Virus Immunotherapy Market Poised to Expand at a Robust Pace by 2026
An oncolytic virus is a special virus that favorably infects and kills cancer cells. These are deployed as a part of cancer immunotherapy and act by selectively targeting cancer cells and carrying out oncolysis. Oncolytic virus is known to not only kill the cancer cells directly but also to stimulate the patient’s own anti-tumour immune responses. The first oncolytic virus immunotherapy was approved in Latvia in 2004 for treatment of skin melanoma. Inevitable changes in the environment occurring due to...
View full press release